



July 26, 2022

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Dear Sirs,

**Sub.: Schedule of Investor Conference Call for Jubilant Pharmova Limited -  
Unaudited Financial Results for the quarter ended June 30, 2022**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on August 2, 2022 after submission of the financial results for the quarter ended June 30, 2022 to the Stock Exchanges. Details of the Conference Call are attached.

This is for information and record.

Thanking you,

Yours faithfully,  
For Jubilant Pharmova Limited

Rajiv Shah  
Company Secretary

Encl. a/a

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Pharmova Limited**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)


**Noida, Tuesday, July 26, 2022**

---

**Conference call on Tuesday, Aug 02, 2022 at 05:00 pm IST**

---

The management team of Jubilant Pharmova Limited - an integrated global Pharmaceutical, Contract Research Development and Manufacturing Organisation and Proprietary Novel Drugs company - will host a conference call for analysts and investors on Tuesday, Aug 02, 2022, at 05:00 PM IST. The call will commence with a brief management discussion on the financial performance for the quarter ended June 30, 2022, followed by an interactive Question & Answer session.

Diamond Pass Log-In	
<b>Pre-registration:</b>	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p>  <p>Click here to <b>ExpressJoin the Call</b></p> <p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode &amp; pin to connect to call.</p>
<b>Conference Dial-In Numbers</b>	
Universal Access:	<b>+ 91 22 6280 1141</b> <b>+ 91 22 7115 8042</b>
Toll Free Number:	USA: <b>1 866 746 2133</b> UK: <b>0 808 101 1573</b> Singapore: <b>800 101 2045</b> Hong Kong: <b>800 964 448</b>
Replay Facility:	Available from August 02 to August 09, 2022 <b>Dial in No.:</b> +91 22 7194 5757 / +91 22 6663 5757 <b>Playback ID:</b> 65703

-ENDS -

---

## **About Jubilant Pharmova Limited**

*Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. The company is also involved in the manufacturing of Active Pharmaceutical Products through a US FDA approved facility in Nanjangud, Karnataka. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: [www.jubilantpharmova.com](http://www.jubilantpharmova.com)*

---

### **For more information please contact:**

---

Vineet V Mayer  
Jubilant Pharmova Limited  
Ph: +91-120 4361103  
E-mail: [vineet.mayer@jubl.com](mailto:vineet.mayer@jubl.com)

Siddharth Rangnekar / Mit Shah  
CDR India  
Ph: +91 97699 19966 / 99201 68314  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[mit@cdr-india.com](mailto:mit@cdr-india.com)

**Disclaimer:** *Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*

